How the price of AstraZeneca's buyout of CinCor fell by $1.4B

Nicole DeFeudis

Editor

CinCor scored a $1.8 billion buyout deal with AstraZeneca earlier this month, but according to recently released documents, it almost walked away from the deal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

How the price of AstraZeneca's buyout of CinCor fell by $1.4B

Nicole DeFeudis

Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Updated: White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Pharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most favored nation' plan to cut drug prices

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

It's been three months without a biotech IPO

How the price of As­traZeneca's buy­out of Cin­Cor fell by $1.4B

Editor

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

How the price of AstraZeneca's buyout of CinCor fell by $1.4B